Clinical Trials Logo
  1. Home
  2. Irritable Bowel Syndrome
  3. NCT01678781
  4. Details
NCT01678781 Clinical Trial

Open International Study on Quality of Life in Irritable Bowel Syndrome (IBS) Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide

Irritable Bowel Syndrome Clinical Trial

Official title:
Open International Study on Quality of Life in IBS Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01678781
Other study ID # P13-678
Secondary ID
Status Completed
Phase N/A
First received July 13, 2012
Last updated September 6, 2013
Start date July 2012
Est. completion date August 2013

Study information
Verified date September 2013
Source Abbott
Contact n/a
Is FDA regulated No
Health authority Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal ProductsChina: Ethics CommitteeEgypt: Ministry of Health and PopulationMexico: Federal Commission for Sanitary Risks Protection
Study type Observational

Clinical Trial Summary

A study to evaluate, by country and overall, the changes from baseline of the irritable bowel syndrome quality of life (IBS QoL) total score after 4 and 8 weeks of treatment with Duspatalin® or Dicetel® in IBS patients.

Recruitment information / eligibility
Status Completed
Enrollment 607
Est. completion date August 2013
Est. primary completion date August 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Irritable bowel syndrome patients diagnosed by Rome III criteria (18 years or older)

Exclusion Criteria:

- Pregnancy and lactation

- Specific contraindications to mebeverine hydrochloride or pinaverium bromide

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
China Site reference ID/Investigator# 94519 Beijing
China Site reference ID/Investigator# 94521 Guangzhou
China Site reference ID/Investigator# 95475 Guangzhou City
China Site reference ID/Investigator # 94516 Shanghai
China Site reference ID/Investigator # 94517 Shanghai
China Site reference ID/Investigator # 94518 Shanghai
China Site reference ID/Investigator # 94515 Wuhan
Egypt Site Reference ID/Investigator# 95908 Alexandria
Egypt Site reference ID/Investigator# 95900 Cairo
Egypt Site reference ID/Investigator# 95901 El Sharkya
Egypt Site reference ID/Investigator# 95902 Giza
Egypt Site reference ID/Investigator# 95903 Giza
Egypt Site Reference ID/Investigator# 95906 Port Said
Mexico Site reference ID/Investigaot# 94525 Guadalajara
Mexico Site refernce ID/Investigator# 94527 Mexico City
Mexico Site reference ID/Investigator# 94523 Tampico
Poland Site Reference ID/Investigator# 85297 Bialystok
Poland Site reference ID/Investigator# 85314 Bialystok
Poland Site Reference ID/Investigator# 85298 Bydgoszcz
Poland Site Reference ID/Investigator# 85293 Katowice
Poland Site Reference ID/Investigator# 85296 Lodz
Poland Site reference ID/Investigator# 85313 Olsztyn
Poland Site Reference ID/Investigator# 85294 Poznan
Poland Site Reference ID/Investigator# 85295 Poznan

Sponsors (2)
Lead Sponsor Collaborator
Abbott CHILTERN International GmbH

Countries where clinical trial is conducted

China,  Egypt,  Mexico,  Poland, 

Outcome
Type Measure Description Time frame Safety issue
Primary Change in Irritable Bowel syndrome (IBS) quality of life (QoL) measure (IBS-QoL) to assess the impairment of QoL in IBS patients From baseline up to the week 8 visit No
Secondary Change in abdominal pain From baseline up to the week 8 visit No
Secondary Change in bloating From baseline up to the week 8 visit No
Secondary Change in feeling of abdominal distension From baseline up to the week 8 visit No
Secondary Change in stool frequency From baseline up to the week 8 visit No
Secondary Change in stool form From baseline up to the week 8 visit No
Secondary Change in straining of evacuation From baseline up to the week 8 visit No
Secondary Change in urgency of evacuation From baseline up to the week 8 visit No
Secondary Change in feeling of incomplete evacuation From baseline up to the week 8 visit No
See also
  Status Clinical Trial Phase
Completed NCT03720314 - Microbiota Profiling in IBS
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT05213910 - Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains N/A
Recruiting NCT05985018 - Traditional Dietary Advice Vs. Mediterranean Diet in IBS N/A
Completed NCT04486469 - Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study. N/A
Completed NCT06407609 - Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS N/A
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04145856 - Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico Phase 4
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Active, not recruiting NCT03586622 - One Year Home Monitoring and Treatment of IBS Patients N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Not yet recruiting NCT05157867 - In Vivo Effects of Amylase Trypsin Inhibitors N/A
Not yet recruiting NCT05100719 - The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) N/A
Recruiting NCT05001997 - Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome N/A
Recruiting NCT02953171 - Probiotics in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03266068 - Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Completed NCT02977975 - Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT02980406 - The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level N/A
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3